A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.

NCT01916447 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Gastrointestinal Tumors

Interventions

DRUG: TAS-102
DRUG: CPT-11
DRUG: Bevacizumab

Sponsor

Taiho Oncology, Inc.